More case studies. More interaction. More of the science shaping modern drug discovery.
Explore the sessions, speakers and organizations shaping this year's meeting.
NEW: Pfizer on Harnessing AI & Cryo-EM to Accelerate Structural Determination
Hear how Huixian Wu, Head of Structural Biology at Pfizer, is combining machine learning-guided construct optimization with cryo-EM to solve dynamic and difficult targets, including membrane proteins and large complexes, faster and with greater confidence.
NEW: Insitro on Construct Strategy, Stability & Biological Fidelity
Move beyond chasing expression yield. Nikhil Jain shares how prioritizing functional competence and conformational relevance has prevented misleading ligand poses and downstream design errors, a practical shift that changes how teams approach SBDD from the start.
NEW: Harvard Medical School on Designing Fusion Protein Therapeutics Using 3D Cell-Surface Models
Jeffrey Way presents a novel approach to rational protein design, building 3D structural models of the red blood cell surface to contextualize drug-target interactions and design fusion proteins that achieve tissue targeting without unintended side effects.
NEW: Vividion Therapeutics on Embedding Structural Biology in a Platform-Driven Discovery Model
Steffen Bernard shares what it looks like to run structural biology in a fast-moving platform model, using single-particle cryo-EM to resolve divergent binding mechanisms and identify alternative sites on well-studied targets for differentiated pharmacology.
NEW: AI Proteins on Evaluating Co-Folding Models Against Clinical Reality
Frank Teets presents a rigorous assessment of where co-folding models have delivered and where they have not, benchmarking predicted binding modes and interaction interfaces against functional assays, in vivo behaviour and translational readouts.
NEW: Sanofi on Closing the Loop Between Structural Biology & AI
Ryan Casner shares how targeted experimental data can directly improve AI-driven nanobody structure prediction, identifying low-confidence regions computationally and designing custom experiments to generate training data that sharpens model accuracy.
NEW: Confo Therapeutics on Stabilizing Functional GPCR States for Structure-Guided Discovery
Beatrice Li demonstrates how ConfoBodies stabilize GPCRs in functionally relevant conformations, enabling high-quality structural analysis of a notoriously difficult target class and opening the door to De Novo nanobody discovery.
NEW: Gilead Sciences on Resolving a Hidden Allosteric Pocket in an Antiviral Target
Xinchao Yu reveals how cryo-EM and complementary biophysics uncovered a ligand-stabilized allosteric binding site in the HSV H-P complex that was absent in apo structures and unpredictable from homology or co-folding models, providing a direct route to new antiviral drug design strategies.
NEW: GSK Vaccines on AI-Enabled Structural Vaccinology Using Gemini
Ilaria Ferlenghi presents a case study on an AI/ML tool pairing structural similarity with functional features to identify novel vaccine targets, and how structure-based epitope mapping is reshaping antibody design for higher affinity and specificity.
Attending Companies Include